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http://www.molecularpain.com/content/10/1/51RESEARCH Open AccessIncreased methylation of the MOR gene proximal
promoter in primary sensory neurons plays a
crucial role in the decreased analgesic effect of
opioids in neuropathic pain
Xue-Long Zhou1†, Li-Na Yu1†, Yin Wang2, Li-Hui Tang2, Yu-Nan Peng1, Jun-Li Cao2 and Min Yan1,2*Abstract
Background: The analgesic potency of opioids is reduced in neuropathic pain. However, the molecular mechanism
is not well understood.
Results: The present study demonstrated that increased methylation of the Mu opioid receptor (MOR) gene
proximal promoter (PP) in dorsal root ganglion (DRG) plays a crucial role in the decreased morphine analgesia.
Subcutaneous (s.c.), intrathecal (i.t.) and intraplantar (i.pl.), not intracerebroventricular (i.c.v.) injection of morphine,
the potency of morphine analgesia was significantly reduced in nerve-injured mice compared with control
sham-operated mice. After peripheral nerve injury, we observed a decreased expression of MOR protein and
mRNA, accompanied by an increased methylation status of MOR gene PP, in DRG. However, peripheral nerve injury
could not induce a decreased expression of MOR mRNA in the spinal cord. Treatment with 5-aza-2′-deoxycytidine
(5-aza-dC), inhibited the increased methylation of MOR gene PP and prevented the decreased expression of MOR in
DRG, thereby improved systemic, spinal and periphery morphine analgesia.
Conclusions: Altogether, our results demonstrate that increased methylation of the MOR gene PP in DRG is
required for the decreased morphine analgesia in neuropathic pain.
Keywords: Neuropathic pain, Epigenetics, OpioidsIntroduction
The treatment of neuropathic pain (NP) continues to be
a major clinical challenge. It is estimated that approxi-
mately half of all patients with neuropathic pain fail to
receive any relief from their symptoms despite taking
prescribed analgesics [1]. Several randomized controlled
trials have shown that opioid analgesics provide greater
pain relief than that of placebos [2] and comparable pain
relief to that of gabapentin and tricyclic antidepressants
[2-4]. However, treating neuropathic pain with opioids is
often discouraged because of its lower efficacy and the
unwanted side effects (such as tolerance and addiction)* Correspondence: yanminnina@126.com
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unless otherwise stated.that can result from long-term and high-dose opioid
therapy [5-14]. It is therefore important to understand
why opioid analgesia is decreased during neuropathic
pain; the answer to this question may provide critical clues
for elucidating the mechanisms of neuropathic pain.
Opioids exert their pharmacological and physiological
effects by binding to their endogenous receptors, which
are found in the central and peripheral nervous systems.
Three types of opioid receptors have been cloned: mu
(μ), delta (δ), and kappa (κ), and all three of these recep-
tors belong to the G protein-coupled receptor superfamily.
Upon agonist binding, these receptors couple to G pro-
teins and affect several signal transduction pathways
that are thought to mediate the broad range of functions
and pharmacological effects of endogenous and exogenous
opioids [15]. Previous studies have suggested that the mu
opioid receptor (MOR) plays a key role in mediating thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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morphine, as well as the tolerance and physical dependence
that develops after prolonged opioid administration [16].
Recently, a growing body of evidence has suggested that
MOR expression is downregulated in the spinal cord
[17-21] and dorsal root ganglion [18,21-24] after nerve in-
jury. This decreased expression of the MOR may partially
explain why opioid analgesia is decreased during neuro-
pathic pain. However, the molecular mechanism driving
these dynamic changes in MOR expression after nerve in-
jury has not been carefully studied. Some studies have
shown that MOR expression can be controlled by manipu-
lating DNA methylation [25-27]. Furthermore, a recent
study reported an increase in global DNA methylation in
the spinal cord after nerve damage in neuropathic mice
[28]. These studies speculated that decreased expression of
the MOR during neuropathic pain may be mediated by in-
creased methylation of the MOR gene promoter. In this
study, we examined a chronic constrictive injury (CCI) pain
model [29], in rodents to demonstrate that increased
methylation of the MOR gene proximal promoter in pri-
mary sensory neurons plays a crucial role in decreasing
morphine analgesia during neuropathic pain.
Results
Morphine analgesia was decreased at the peripheral and
spinal levels but not decreased at the supraspinal level
after nerve injury in neuropathic mice
Thirty minutes after a subcutaneous (s.c.) morphine
(1 mg/kg) injection, which is when the peak analgesic po-
tency is observed, morphine analgesia measured according
to the thermal-withdrawal latency (TWL) was significantly
reduced in nerve-injured but not sham-operated mice on
days 3, 7 and 14 after injury (Figure 1A). When we mea-
sured the TWL using various doses of morphine on day
7 after surgery, we observed that in the control sham-
operated mice, s.c. morphine dose-dependently increased
the TWL and produced significant analgesic action
at doses of 1 mg/kg and 3 mg/kg but not 0.3 mg/kg
(Figure 1B). In nerve-injured mice, morphine failed to
produce a significant analgesic effect at a 1 mg/kg
dose. Morphine produced considerable analgesia in
nerve-injured mice only at the higher doses of 3 mg/kg
and 10 mg/kg (Figure 1C). When we plotted the area
under curve (AUC) of analgesia versus the morphine dose,
a clear rightward shift in the dose–response curve of s.c.
morphine was observed in nerve-injured mice (Figure 1D).
However, systemic morphine (e.g., s.c. morphine) is dis-
tributed throughout the body and acts at various loca-
tions, including peripheral, spinal, and supraspinal sites.
We were unable to determine the sites responsible for
the decreased analgesic effect of systemic morphine
after nerve injury. Therefore, we designed a set of expe-
riments to locate the possible sites that are changed. Weadministered morphine through various routes [intra-
cerebroventricular- (i.c.v.), intrathecal- (i.t.), and intra-
plantar (i.pl.)-injection] in control sham-operated and
sciatic nerve-injured mice and measured their thermal
paw withdrawal responses. We found that i.t. and i.pl.
but not i.c.v. morphine produced a clear rightward shift
in the dose–response curve of morphine in nerve-injured
mice (Figure 1E-G and Additional file 1: Figure S1). These
results indicate that the supraspinal component of mor-
phine analgesia remained intact after nerve injury and
that the decreased effectiveness of systemic morphine in
nerve-injured mice might be caused by reductions in its
potency at the peripheral and spinal levels. Regarding i.
pl. morphine injection, ipsilateral injection of 100 nmol
of morphine only slightly increased the TWL in the in-
jured paw, whereas it considerably increased the TWL
on the contralateral side (Figure 1H). This result sug-
gests that the injection of 100 nmol of i.pl. morphine
produced a partially systemic effect.
Previous studies have demonstrated decreased expres-
sion of the MOR in the dorsal root ganglion (DRG)
[18,21-24] and spinal cord [17-21] after peripheral nerve
injury. However, this result is controversial. We there-
fore assessed the expression of MOR proteins and MOR
mRNA in the spinal cord and DRG. We found that de-
creased morphine analgesia was correlated with CCI-
induced downregulation of the MOR in the spinal cord
and DRG. Peripheral nerve injury but not sham sur-
gery downregulated MOR protein expression in the ip-
silateral spinal cord (Figure 1I) and DRGs (Figure 1K)
on day 7 after surgery. However, unlike the decreased
expression of MOR mRNA in ipsilateral DRGs after
nerve injury (Figure 1L), the expression of MOR
mRNA in the ipsilateral spinal cord was not decreased
(Figure 1J).
Decreased MOR expression in the DRG may contribute
to decreased MOR expression in the spinal cord after
nerve injury
Peripheral MORs are synthesized in DRG neurons,
expressed on the cell bodies of sensory neurons and
then transported to central terminals in the superficial
dorsal horn and to peripheral terminals of peripheral tis-
sues [12,30]. It has been hypothesized that reduced
MOR expression in the dorsal horn of presynaptic afferent
terminals results from a drastic decrease in MOR expres-
sion in the spinal cord and that this reduced expression
contributes to the decreased analgesic potency of i.t. mor-
phine after nerve injury in neuropathic mice. To confirm
this hypothesis, we performed western blots and immuno-
fluorescence stains of the MOR in DRG neurons, spinal
neurons, sciatic nerve tissue and hindpaw skin on day 7
after nerve injury. Using western blot analysis, we found
that MOR expression was significantly decreased at these
Figure 1 Systemic, spinal and periphery morphine analgesia decreased in neuropathic mice. (A) Effects of 1 mg/kg s.c. morphine on TWL in
sham-operated and neuropathic pain mice on days −1, 1, 3, 7 and 14 after surgery. Results are presented as TWL at 30 min after s.c. injection of
morphine or vehicle. ##p<0.05 compared with Sham-Vehicle; *p<0.05 compared with CCI-Vehicle, n=8 in each group. (B, C) Time course of the effects
of s.c. morphine in sham-operated and nerve-injured mice on day 7 after surgery. Results are presented as TWL in seconds, comparison of morphine
analgesia by area under the curve (AUC). *p <0.05, **p <0.01 compared with Vehicle, n=8 in each group. (D-G) Dose–response curves of s.c. (D), i.c.v.
(E), i.t. (F) and i.pl. (G) morphine in sham-operated and nerve-injured mice on day 7 following surgery. The data are presented as AUC analgesic.
**p <0.01 compared with Sham, n=8 mice in each group. (H) Effects of ipsilateral i.pl. morphine on contralateral paw withdrawal latency. Morphine
(30 or 100 nmol i.pl.) was injected into the ipsilateral paw, and the PWL was measured in both the ipsi- and contralateral paw at 10 min following
injection. (I, K) Western blot shows that MOR protein were markedly decreased in the spinal cord (I) and DRG (K) on day 7 after nerve injury, while no
MOR protein decrease was observed in sham-operated mice. (J, L) qRT-PCR shows that MOR mRNA was heavily decreased in DRG (L) on day 7 day after
nerve ligation, while no MOR mRNA decrease was observed in the spinal cord (J) and sham-operated mice. The ratio of MOR/GAPDH in contralateral spinal
cord or DRG sham mice was set at 1 for quantifications. **p <0.01 compared with corresponding contralateral side, n=4 in each group.
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operated mice (Figures 1I, K and 2A, B). Regarding MOR
immunofluorescence staining, there was a substantial de-
crease in the number of MOR-positive neurons in DRGs
on day 7 after nerve injury (Figure 2C). The percentage of
MOR-labeled cells in the sham-operated mice was 23.4 ±
5.67; however, the percentage of MOR-labelled cells in thenerve-injured mice was 9.2 ± 2.15 (p < 0.01, n = 4). Similarly,
MOR expression in the spinal cord was significantly de-
creased on day 7 after nerve injury, particularly in the
superficial lamina (Figure 2D). Many fibers were positively
labeled in the sham-operated sciatic nerve tissue and hind-
paw skin; however, positively labeled nerve fibers were
barely detected after nerve injury (Figure 2E, F).
Figure 2 MOR in primary sensory neuron and its terminals were decreased in neuropathic mice. (A, B) Western blot shows that MOR
protein were markedly decreased in sciatic nerve (A) and hindpaw skin (B) on day 7 after nerve injury when compared with sham-operated mice.
The ratio of MOR/GAPDH in sham mice was set at 1 for quantifications. *p <0.05, **p <0.01, n=4 in each group. (C-F) Immunofluorescence
staining shows that decreased MOR-labeled neurons in DRG (C) and spinal cord dorsal horn (D), decreased MOR-labeled nerve fibers in the sciatic
nerve (E) and hindpaw skin (F) on day 7 after nerve injury. Scales bars= 100 μm.
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potency of peripheral, spinal, and systemic morphine
in neuropathic mice
Peripheral nerve injury has been shown to lead to a de-
creased expression of the MOR in DRGs [18,21-24]; our
experiments confirmed this finding. However, little is
known about the regulatory mechanisms of MOR ex-
pression in the DRGs after nerve injury. Recently, grow-
ing evidence has supported the notion that MOR
expression can be controlled by transcriptional regula-
tion mechanisms that involve DNA methylation [25-27].
To investigate whether expression of the MOR gene is
mediated by DNA methylation, we treated nerve-injured
mice with an inhibitor of DNA methylation, 5′-aza-2′-
deoxycytidine (5-aza-dC). After consecutive intrathecal
injections of 5-aza-dC (5 μg daily for 3 consecutive days,
beginning 30 minutes before surgery), we found that the
reduced systemic (Figure 3A) morphine analgesia (1 mg/
kg, s.c.) previously observed on days 3, 7 and 14 after
nerve injury had improved. When we plotted the AUCof analgesia versus morphine dose on day 7 after 5-aza-dC
treatment, the dose–response curves for s.c., i.t. and i.pl.
morphine were clearly shifted leftward in the mice
treated with 5-aza-dC compared with non-treated mice
(Figure 3B-D and Additional file 2: Figure S2).
Methylation status of the MOR gene promoter after
nerve injury
As a DNA methylation inhibitor had induced an improve-
ment in the analgesic potency of morphine in neuropathic
mice, we attempted to analyze the methylation status of
several MOR gene promoters. There are 20 CpG sites in
the 5′-flanking region (−569 to +31, which covers the
proximal promoter region with the ATG start codon des-
ignated as +1) of the MOR gene. The DNA methylation
status of multiple MOR gene promoters in the DRG of
Sham-Vehicle, CCI-Vehicle, and CCI-5-aza-dC mice were
assessed via bisulfite treatment and sequencing analyses
on day 7 after nerve injury. The evaluation of 20 individual
clones from each mouse revealed that three CpG sites,
Figure 3 5-aza-dC improved morphine analgesia in neuropathic mice. (A) i.t. 5-aza-dC (5 μg, daily for 3 consecutive days, starting 30 minutes
before surgery) improved the effects of s.c. 1 mg/kg morphine in nerve-injured mice on days 3, 7 and 14 after surgery. Results are presented as
TWL at 30 min after s.c. injection of morphin. *p <0.05, **p <0.05 compared with CCI-Vehicle, n=8 mice in each group. (B-D) Dose–response
curves of s.c. (B), i.t. (C) and i.pl. (D) morphine in nerve-injured and 5-aza-dC treatmented mice on day 7 after nerve injury. The data are presented
as AUC analgesic. *p <0.05 compared with CCI-Vehicle, n=8 mice in each group.
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(over 40% of the clones) after nerve injury and that these
three methylated sites were demethylated at least 15% in
the presence of 5-aza-dC (Figure 4A, B and Additional file
3: Figure S3A). These three sites are located upstream,
close to the proximal promoter (PP)-derived transcription
initiation site (TIS). Furthermore, we examined whether
the change in methylation status was specific to this PP
region, which is known to be a major promoter for the
MOR gene, or if it also occurred in other regions. An ana-
lysis of the methylation status of the upstream region of
the distal promoter (DP) (from −980 to −1721, containing
11 CpG sites) was performed. These sites were highly
methylated in the Sham-Vehicle mice (more than 70%
methylation, as high as 100%). This hypermethylation was
unchanged in the CCI-Vehicle and CCI-5-aza-dC mice
(Figure 5A and Additional file 3: Figure S3B). We also
found that 5-aza-dC prevented the downregulation of
MOR mRNA and MOR proteins in the DRG due to nerve
injury (Figure 5B, C). Consistent with the expression pat-
tern of MOR mRNA and MOR proteins in the spinal cord
after nerve injury, the expression of MOR mRNA in the
spinal cord unchanged (Figure 5D). However, increased
expression of MOR protein was observed in the spinal
cord after 5-aza-dC treatment in neuropathic mice
(Figure 5E). In addition, we analyzed the methylation sta-
tus of several MOR gene promoters in the spinal cord; no
significant changes in methylation status were found in ei-
ther the proximal or distal promoter of the MOR gene
after nerve injury or treatment with 5-aza-dC (Additional
file 4: Figure S4).
Increased MOR expression in the DRG may contribute to
the increased MOR expression in the spinal cord induced
by 5-aza-dC
Next, we investigated whether the increased expression
of MOR proteins after treatment with 5-aza-dC led toan anterograde transport of MOR proteins along the sci-
atic nerve to peripheral nerve terminals in the skin and/
or along the dorsal root to central terminals in the dor-
sal horn of the spinal cord. We performed western blots
and immunofluorescence stains on DRG neurons, spinal
neurons, sciatic nerve tissue and hindpaw skin after
treatment with 5-aza-dC. We found that MOR expres-
sion was increased in mice treated with 5-aza-dC com-
pared with nerve-injured mice according to western blot
analysis (Figures 5C, E and 6A, B). On immunofluores-
cence stains, the number of MOR-positive neurons in
the DRG after 5-aza-dC treatment was substantially in-
creased (Figure 6C). The percentage of labeled cells in
nerve-injured mice was 8.7 ± 2.24, and the percentage of
labelled cells in mice treated with 5-aza-dC was 17.9 ±
4.07 (p < 0.01, n = 4). A similar increase in the number of
labeled neurons was detected in the spinal cord, sciatic
nerve tissue and hindpaw skin of mice treated with 5-aza-
dC (Figure 6D-F).
In vitro, increased methylation of the MOR promoter
represses its promoter activity
Finally, the relevance of the methylation status of the
MOR gene promoter was investigated using reporter gene
analyses. To mimic the endogenous methylation status of
the MOR gene promoter, MOR promoter plasmids [31]
fused with luciferase containing pL450 (PP only, −450
to −249), pLup (DP only, −1,326 to −775) or pL1.3 k (DP
and PP, −1,326 to −249) (Figure 7A) were methylated
using either partial methylase HpaI, HpaII or full methyl-
ase SssI in vitro. Then, the resulting in vitro-methylated
MOR promoter/reporter constructs were individually
transfected into SH-SY5Y cells. An unmodified promoter
(control) was also introduced into SH-SY5Y cells. Partial
methylation of the luciferase constructs partially reduced
promoter activity compared with the control constructs,
whereas full methylation of the constructs completely
Figure 4 (See legend on next page.)
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Figure 4 Methylation statuses of MOR gene proximal promoter (PP) in DRG. (A) The PP region of the MOR gene contains 20 putative
methyl CpG sites from −569 to +33 (with the ATG start codon designated +1). The numbers at the top of the figure (No. CpG) are arbitrary
designations to indicate each methyl CpG site. ppTIS indicates the TISs of the major MOR PP containing four sites. Each row of circles represents
a single cloned allele, and each circle indicates a single CpG site at a specific location. The methylation statuses of 20 individual clones were
analyzed for each mouse. The filled and open circles represent the methylated and unmethylated CpG sites, respectively. (B) Methylation changes
within the PP region of MOR gene. The percentages of methylation at −388, −344 and −255 CpG sites significantly increased in DRG after nerve
injury and reduced after 5-aza-dC treatment (5 μg, daily for 3 consecutive days, starting 30 minutes before surgery). **P<0.01compared with
Sham-Vehicle mice; ##p <0.01 compared with CCI-Vehicle mice, n=4 in each group. (C) Samples of the sequence fluorograms obtained using
bisulfite genomic sequencing of DNA isolated from the DRG of Sham-Vehicle or CCI-5-aza-dC and CCI-Vehicle mice are shown. Arrows indicate
methylated and nonmethylated sequences of CpG site −388, −344, and −255.
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methylation data suggest that methylation of the promoter
may contribute to the repression of MOR gene transcrip-
tion in a methylation density-dependent manner.Discussion
Neuropathic pain due to peripheral nerve injury is often
less responsive to opioids in clinical and experimental ani-
mal models. Furthermore, the present study has shown
that increased methylation of the MOR gene proximal
promoter in primary sensory neurons plays a crucial role
in the decreased analgesic effect of opioids in neuropathic
mice.Opioids for neuropathic pain
In clinical practice, opioids often fail to provide effective
analgesia for neuropathic pain [5-8]. Similar results have
been observed in experimental animal models [9-14].
Consistent with those findings, the present study observed
a marked decrease in the analgesic potency of systemic
(s.c.) morphine in mice with sciatic nerve injury-induced
neuropathy. Furthermore, our study revealed that the
decreased effectiveness of systemic morphine in nerve-
injured mice was caused by reduced potency at the per-
ipheral and spinal levels but not at the supraspinal level.
This result is consistent with that of a previous study by
Rashid et al. [24]. In the present study, we also found that
the loss of peripheral morphine analgesia was injury-
specific; however, a previous study reported that i.pl.
morphine was more effective in the ipsilateral paw than
the contralateral paw in rats with spinal nerve ligation-
induced neuropathy [11]. It is worth noting that the
dose of morphine that produced this effect (200 μg, i.pl.)
in the previous study was much higher than the dose used
in our study (30 nm, which is approximately 1 μg, i.pl.).
The systemic effects of such higher doses cannot be ex-
cluded. In our experiment, an ipsilateral injection of
100 nmol of i.pl. morphine produced analgesia in the
contralateral paw, indicating the presence of systemic
effects at this higher dose (Figure 1H). Nevertheless,
other factors, such as the use of different neuropathy
models or different species of animals, may beresponsible for the discrepancies between our results
and those of previous studies.The MOR and neuropathic pain
Previous studies have shown that the downregulation of
MOR expression that occurs in the spinal cord [17-21]
and DRG [18,21-24] may contribute to decreased opioid
analgesia after nerve injury. However, the specific sites
where decreased MOR expression occurs remain contro-
versial. To determine the specific sites where decreased
MOR expression occurs after peripheral nerve injury, we
examined MOR expression in the spinal cord and DRG
following sciatic nerve injury. Consistent with previous
behavioral data, we found that nerve injury drastically
decreased MOR expression in the spinal cord and DRG
on day 7 after surgery. However, we also found that MOR
expression was decreased at both the protein and mRNA
levels in the DRG but not the spinal cord. There was no
decreased expression of MOR mRNA in the spinal cord
after nerve injury. This result is partially consistent with
that of a recent study by Lee et al. [23], which reported
that MOR expression was decreased at both the protein
and mRNA levels in the DRG on day 7, but remained un-
changed at the protein level in the spinal cord until day 35
following L5 spinal nerve ligation (SNL). Our finding of a
decrease in MOR expression in the spinal cord on day 7
following peripheral nerve injury is consistent with nu-
merous previous reports [17,18,20,32]. For example, Goff
et al. [32] reported a drastic decrease in MOR expression
in the spinal cord 7 days following tight ligation of the sci-
atic nerve. In addition, Zhang et al. [18] reported down-
regulation of the MOR in rats 7 days after peripheral
axotomy. However, the report by Zhang et al. involved a
considerable species difference with regard to the time of
reduced MOR expression following axotomy. Whereas
axotomy caused a reduction in spinal cord MOR expres-
sion in rats on day 7, axotomy caused a decrease in spinal
cord MOR expression in monkeys on day 14 after nerve
injury. We speculate that species difference may also ac-
counts for the different time of reduced MOR expression
observed in our study of mice compared to the SNL ex-
periments in rats by Lee et al. [23]. Moreover, the use of
Figure 5 (See legend on next page.)
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Figure 5 Methylation statuses of MOR gene distal promoter (DP) in DRG and the expression of MOR change after 5-aza-dC treatment.
(A) The DP region of the MOR gene contains 11 putative methyl CpG sites from −1721 to −784. dpTIS indicates a TIS of the DP. (B, D) qRT-PCR
show that MOR mRNA was increased in DRG after treatment with 5-aza-dC (5 μg, daily for 3 consecutive days, starting 30 minutes before surgery)
(B), while no MOR mRNA increase was observed in the spinal cord (D). The ratio of MOR/GAPDH in Sham-Vehicle mice was set at 1 for quantifications.
*p <0.05, **p <0.05 compared with Sham-Vehicle mice; ##p <0.01 compared with CCI-Vehicle mice, n=4 in each group. (C, E) Western blot shows that
MOR protein was increased in DRG (C) and spinal cord (E) after treatment with 5-aza-dC (5 μg, daily for 3 consecutive days, starting 30 minutes
before surgery). The ratio of MOR/GAPDH in Sham-Vehicle mice was set at 1 for quantifications. *p <0.05, **p <0.01 compared with Sham-Vehicle mice;
##p <0.01 compared with CCI-Vehicle mice, n=4 in each group.
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differences.
In addition, peripheral MORs are synthesized in DRG
neurons and expressed on cell bodies of sensory neurons
and then transported to central terminals in the superfi-
cial dorsal horn and peripheral terminals in peripheral
tissues [12,30]. There may be a reduction in MOR ex-
pression in the presynaptic afferent terminals of the
spinal dorsal horn as a result of the drastic decrease inFigure 6 MOR in peripheral sensory neuron and its terminals were in
that MOR protein were markedly increased in sciatic nerve (A) and hindpa
days, starting 30 minutes before surgery and detected on day 7 after nerve
n=4 in each group. (C-F) Immunofluorescence staining shows that increase
increased MOR-labeled nerve fibers in the sciatic nerve (E) and hindpaw sk
starting 30 minutes before surgery). Scales bars= 100 μm.MOR expression that occurs in the spinal cord; this
process may contribute to the decreased analgesic potency
of i.t. morphine observed in neuropathic mice. Several
lines of evidence support this hypothesis. Besse et al. [33]
reported that peripheral nerve injury results in a loss of
spinal MORs, which are predominately distributed in the
superficial dorsal horn. As previously reported [34-36],
MOR expression occurs on both dorsal horn neurons and
the presynaptic terminals of laminas I and II (both ofcreased after treatment with 5-aza-dC. (A, B) Western blot shows
w skin (B) after treatment with 5-aza-dC (5 μg, daily for 3 consecutive
injury) when compared with CCI-Vehicle mice, *p <0.05, **p <0.01,
d MOR-labeled neurons in DRG (C) and spinal cord dorsal horn (D),
in (F) after treatment with 5-aza-dC (5 μg, daily for 3 consecutive days,
Figure 7 Repression of MOR promoter-driven transcription by CpG methylation. (A, B) Three different luciferase (LUC) constructs (pL450,
pLup and pL1.3 k) were mock methylated (control) or in vitro methylated with HapI, HpaII (partial) or SssI (full) methylase and transfected into SH-
SY5Y cells. The results are given as luciferase activity normalized against cotransfected pCH110 β-galactosidase activity. The data shown are the
means of three independent experiments with at least two different plasmid preparations. The control with none methylase was set at 1 for
quantifications. #P<0.05, **’##’$$P<0.01, ***,###,$$$P<0.001 compared with control, n=4 in each group.
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the outer portion of lamina II contain a dense plexus of
substance P-containing axons, most of which are primary
afferent terminals. Moreover, Kondo et al. [37] found that
the analgesic effect of opioids in the spinal cord may be
mediated by opioid receptors located in C-fiber terminals.
On western blotting and immunofluorescence staining of
DRG neurons, spinal neurons, sciatic nerve tissue and
hindpaw skin on day 7 after nerve injury, we observed
decreased expression of MOR proteins in the cell bodies
of primary sensory neurons in the DRG after nerve in-
jury. This decreased MOR expression may reduce the
transport of morphine to both the peripheral and cen-
tral terminals of primary sensory neurons in the DRG,
decreasing the analgesic effect of spinal and peripheral
morphine.Methylation modification and the MOR
Epigenetic control, which includes DNA methylation and
the histone modifications acetylation and methylation, al-
ters the ability of transcriptional machinery to access DNA,
thereby regulating gene expression [38]. Recently, Uchida
et al. reported that nerve injury upregulates neuron restric-
tive silencer factor (NRSF) expression and promotes NRSF
binding to the neuron-restrictive silencer element (NRSE)
within the MOR gene in DRG neurons. As NRSF binds to
NRSE, it represses the transcription of the MOR gene
through HDAC-mediated mechanisms [39]. Other than the
histone modification mechanisms, the MOR has also been
reported to be regulated via DNA methylation in opiate
users and this regulation may cause pain [40-42]. However,
it is unclear whether DNA methylation is critical for the
regulation of MOR expression after nerve injury. In the
present study, we showed that increased methylation of the
MOR gene proximal promoter in the DRG plays a crucialrole in the regulation of MOR expression under neuro-
pathic pain conditions.
In mammals, there are two general mechanisms by
which DNA methylation inhibits gene expression [43].
The first mechanism involves modifying cytosine bases
to directly inhibit the association of DNA binding factors
due to steric hindrance. The second and more important
mechanism of inhibition involves various proteins that
recognize methylated CpG sites and recruit transcriptional
co-repressor molecules to silence transcription. The si-
lencing of methylated promoters usually requires
Methyl-CpG-binding proteins (MBPs), which specific-
ally recognize methylated CpG sites. To date, five MBPs
have been identified: MBD1, MBD2, MBD3, MBD4, and
MeCP2. MeCP2 can bind to a single methylated CpG
site, whereas other MBPs [e.g., Methyl-CpG-binding
proteins 1 (MeCP1)], generally bind to DNA containing
at least 12 symmetrically methylated CpGs [44]. Because
only three scattered CpGs (at −388, −344, and −255)
out of the 20 CpG sites in the MOR promoter showed
changes in their methylation status, we believe that
MeCP2 may serve as a possible mediator of transcrip-
tional repression of the MOR gene. Regarding the co-
repressor molecules, two recent studies reported that
MeCP2 recruits mSin3A and Brg1 to generate a tran-
scriptionally repressed chromatin structure to inhibit
expression of the MOR gene [25,45].
Conclusion
In conclusion, the present study demonstrated that
DNA methylation directed epigenetic gene silencing of
MOR genes in the DRG is responsible for the decreased
efficacy of opioids after nerve injury. Elucidation of regu-
latory mechanisms for DNA methylation after nerve in-
jury might provide novel therapeutic targets for the
neuropathic pain.
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Experimental animals
Experiments were performed on adult (weighing 20–
25 g) male C57BL/6 J mice. Animals were obtained from
Experimental Animal Center of Zhejiang University and
were on a 12:12 light–dark cycle with a controlled room
temperature (23-24°C, 60-70% relative humidity), and re-
ceived food and water ad libitum. All experiments were
performed in according with the guidelines of the In-
ternational Association for the Study of Pain [46] and
were approved by the Animal Research Committee of
Zhejiang University.
Drug application
Morphine hydrochloride and 5-aza-2′-deoxycytidine (5-
aza-dC) were purchased from Sigma (St. Louis, MO) were
dissolved in physiological saline. Saline was used for con-
trol injections. Intraplantar injections (i.pl.) were given
using a Hamilton microsyringe connected to polyethylene
tubing with a 30-gauge hypodermic needle at the tip. The
volume of injection was 20 μl in thermal paw withdrawal
tests. The intrathecal injections (i.t.) were performed free-
hand between spinal L5 and L6 segments according to the
method of Hylden and Wilcox [47]. The exact placement
of the drug substances was checked by a quick flicking
motion of the mouse’s tail upon entry of needle. The In-
tracerebroventricular injections (i.c.v.) were carried out
into the left lateral ventricle of mice. Injections were per-
formed using a Hamilton microsyringe fitted with a 26-
gauge i.c.v. needle according to the method of Haley and
McCormick [48]. The site of injection was 2 mm caudal
and 2 mm lateral to the bregma and 3 mm in depth from
the skull surface. Both i.t. and i.c.v. injections were given
in a volume of 5 μl. The mice received the subcutaneous
injections (s.c.) in a volume of 0.1 ml/10 g of body weight.
All doses of drugs are based on the results of preliminary
experiments.
Chronic constrictive injury model
Chronic constrictive injury (CCI) model was performed
following the method of Bennett and Xie. In brief, mice
were anesthetized with sodium pentobarbital (40 mg/kg,
intraperitoneal injection). Left sciatic nerve was exposed
at midthigh level through a small incision, and a unilat-
eral constriction injury just proximal to the trifurcation
was performed with three loose ligatures using a 5–0 silk
thread (spaced at a 1-mm interval). In sham-operated
animals, the nerve was exposed but not ligated. The in-
cision was closed in layers, and the wound was treated
with antibiotics.
Measurement of thermal hyperalgesia
Thermal hyperalgesia was measured using the thermal-
withdrawal latency (TWL) according to the methoddescribed previously [49]. In brief, mice were placed in
clear plastic chambers (7-9-11 cm) and allowed to
acclimatize to the environment for 1 h before drug ap-
plication. The heat source was focused on a portion of
the hindpaw, which was flush against the glass, and a ra-
diant thermal stimulus was delivered to that site. The
nociceptive endpoints in the radiant heat test were the
characteristic lifting or licking of the hind paw. The time
to the endpoint was considered the TWL. The radiant
heat intensity was adjusted to obtain basal TWL of 10–
12 s. An automatic 20 s cutoff was used to prevent tissue
damage. After 1 h of adaptation, morphine was injected
s.c., i.t., i.c.v., or i.pl., and the thermal withdrawal laten-
cies were measured at every 10-min interval until
60 min. AUC analgesic was measured by deducting the
area under the time-response curve of saline (AUC-
saline) from the area under the time-response curve of
morphine (AUC-morphine). In some experiments, the
paw withdrawal latencies at 10 or 30 min after drug ad-
ministration were measured. The behavioral testing was
performed by an investigator blinded to the treatment.
Real-time quantitative RT-PCR (qRT-PCR)
Under deep anesthesia (sodium pentobarbital, 60 mg/kg,
intraperitoneal injection), L4-L5 DRGs and L4-L5 spinal
cord segment was quickly removed. Total RNA was iso-
lated with TRIzol reagent (Invitrogen) according to the
manufacturer’s instructions. cDNA was then synthesized
using a Thermo Scientific Verso cDNA synthesis kit
(ABgene, Thermo Scientific) with oligo(dT) primer.
Quantitative RT-PCR (qRT-PCR) was performed with a
DyNAmo Flash SYBR Green qPCR kit (Thermo Scien-
tific). The thermal cycle conditions used to assess the
expression of MOR was: 95°C for 3 minutes; 40 cycles
of 95°C for 15 seconds, 58°C for 30 seconds, and 72°C
for 30 seconds and finally 30 min at 72°C with the
primers: MOR (qRT-PCR), forward TCCTGGTCATG
TATGTGATTGT A AGA and reverse CGTGCTAGTG
GCTAAGGCATCT; GAPDH, forward TATGACTCC
ACTCACGGCAAAT and reverse GGGTCTCGCTCC
TGGAAGAT. Relative mRNA levels were calculated
using the 2 − ΔΔCT method.
Western blot analysis
Under deep anesthesia, the L4-L5 DRGs and L4-L5 spinal
cord segment, sciatic nerves and plantar surface of hind-
paw skin of mice were quickly extracted and stored in li-
quid nitrogen. Tissue samples were homogenized in lysis
buffer (12.5 μl/mg tissue) containing a mixture of protease
inhibitors (Roche) and PMSF (Sigma). After incubating in
ice for 30 min, samples were centrifuged at 10,000 rpm
for 15 min at 4°C. The supernatants were used for West-
ern blotting. Equal amount of protein (~30 μg) was loaded
and separated in 10% Tris-Tricine SDS-PAGE gel. The
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difluoride (PVDF) membranes (Amersham Bioscience).
The membranes were blocked in 5% non-fat milk for 1 h
at room temperature (RT), and incubated overnight at 4°C
with rabbit anti-MOR antibody (Neuromics, 1:1,000)
or anti-GAPDH antibody (Cell Signaling Technology,
1:2000) primary antibody. The blots were then incubated
with the secondary antibody, goat anti-rabbit IgG con-
jugated with horseradish peroxidase (HRP) (1:1000, Cell
Signaling Technology), for 2 h at room temperature.
Signals were finally visualized using enhanced chemilu-
minescence (ECL, Pierce) and the blots were exposed by
The ChemiDoc™ XRS + image system (Bio-Rad; Hercules).
All Western blot analysis was performed at least three
times, and consistent results were obtained. Western blot
densitometry analysis of signal intensity was performed
using Quantity One 4.6.2 (Bio-Rad; Hercules) and levels of
MOR from densitometry were normalized to GAPDH.
The blot density from control groups was set as 100%.
Immunohistochemistry
Mice were deeply anesthetized and undergone sternot-
omy, intracardially perfuse with 20 ml saline followed by
4% ice-cold paraformaldehyde in 0.1 mol/l phosphate
buffer (PB). L4-L5 DRGs, L4-L5 spinal cord segments,
sciatic nerves, and plantar surface of hindpaw skin were
removed, post-fixed in 4% paraformaldehyde for 3 h,
and subsequently allowed to equilibrate in 30% sucrose
in PB overnight at 4°C. DRG and transverse spinal cord
sections (15 μm), sciatic nerve sections (10 μm) and skin
sections (40 μm) were cut on a cryostat and every fifth
section was collected in PB. After washing in phosphate
buffer saline (PBS), the tissue sections were incubated in
PBS containing 5% normal goat serum and 0.3%
TritonX-100 at room temperature for 30 min. The sec-
tions were incubated overnight at 4°C with rabbit anti-
MOR antibody (Neuromics, 1:500) followed by Rhoda-
mine Red™-X goat anti-rabbit IgG (Invitrogen, 1:500) for
2 h at room temperature. Nonspecific staining was de-
termined by excluding the primary antibodies. Sections
were rinsed, mounted, and cover-slipped with glycerol
containing 2.5% of anti-fading agent DABCO (Sigma)
and stored at −20°C in the dark. Images were captured
using a fluorescent microscope (DMIRB, Leica, Germany).
The number of immunoreactive neuronal profiles was
counted in a blinded fashion. Twenty sections were se-
lected from four mice in each group. For DRG sections,
Neuronal cell bodies were identified by the presence of a
nucleus. The density threshold for positive staining was
determined by averaging three cell bodies in each section
that were judged to be minimally positive. All neurons for
which the mean density exceeded the threshold were
counted as positive, and the positive cells were expressed
as a percentage of total counted neurons.Methylation analysis
Genomic DNA from the DRG was isolated using the
Wizard Genomic DNA Purification Kit (Qiagen) and
linearized with the restriction enzyme EcoRV. Bisulfite
treatment of DNA was carried out according to the
manufacturer’s recommendations (EZ DNA Methylation-
Gold Kit; Zymo Research). The resulting bisulfite-
modified DNA was amplified by PCR. The PCR condi-
tions were as follows: 94°C for 2 min, followed by 35 cycles
of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for
1 min, and finally 30 min at 72°C. After PCR amplifi-
cation, the PCR products were purified using a gel extrac-
tion kit (QIAGEN) and cloned into the pCR2.1-TOPO
vector (Invitrogen) according to the manufacturer’s in-
structions. Twenty clones containing an insert of the cor-
rect size from each mouse were randomly chosen for
DNA sequencing. The primers specific for methylated
(methylation-specific PCR [MSP]) MOR DNA were de-
signed as follows: MOR (PP), forward GTGGGTAAAG
GATAATATTAATAATTTT and reverse CAACTTAC
AAAAACTAAAAAATCAAAAC; MOR (DP), forward
GAGAAGAAGATTGAGGTAAAGTAGTA T and reverse
CATACCAAATCTACTCTCCTAAACCTAC.
In vitro methylation of reporter plasmid and reporter
gene assays
In vitro methylation of reporter plasmids was carried
out as reported previously [25]. Briefly, methylases SssI,
HpaI and HpaII were used to methylate MOR pro-
moter/luciferase reporter constructs following the rec-
ommendations of the manufacturer (New England
Biolabs). Complete methylation was determined by
digesting the DNA constructs with the methylation-
sensitive restriction enzyme Bstu1, HpaI, HpaII (New
England Biolabs) respectly and running the products on
an agarose gel. Only DNA that was completely methyl-
ated was used. The construction of all luciferase fusion
plasmids (pL450, pLup, and pL1.3 k) used in this study
has been described previously [31]. SH-SY5Y cells were
plated 24 h prior to transfection at a density of 3×105
cells/well in six-well culture plates. Transfection was
carried out using the effectene transfection reagent
(QIAGEN) as described by the manufacturer. Cells were
washed and lysed with lysis buffer (Promega) 48 h after
transfection. To correct differences in transfection effi-
ciency, a one-fifth molar ratio of a pCH110 plasmid
(Amersham Biosciences) containing the β-galactosidase
gene under the simian virus 40 promoter was included
in the transfection to normalize values. The luciferase
and galactosidase activities of each lysate were de-
termined as described by the manufacturers (Promega
and Tropix, respectively). Each normalized value rep-
resents the average of at least three independent
determinations.
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Data are expressed as mean±SEM. Statistical analysis be-
tween two samples was performed using Student t test.
Statistical comparison of more than two groups was per-
formed using one-way ANOVA followed by a Tukey post
hoc test. The significance of any differences in thermal la-
tency in behavior test was assessed using two-way ANOVA.
“Time” was treated as “within subjects” factor and “treat-
ment” was treated as a “between subjects” factor. The area
under the pain threshold change versus time curve was cal-
culated by GraphPAD Prism5 (Graph Pad Software, Inc.,
San Diego, CA) in some behavioral test. Statistical analyses
of data were generated using GraphPAD Prism 5. All p
values given are based on two-tailed tests. A value of p less
than 0.05 was considered as statistically significant.Additional files
Additional file 1: Figure S1. Spinal and periphery morphine analgesia
decreased in neuropathic pain mice. Time course of i.c.v. (A and B), i.t.
(D and E) and i.pl. (G and H) morphine in sham-operated and nerve-injured
mice at 7 days after surgery. Results are presented as TWL in seconds,
comparison of morphine analgesia by AUC. *P<0.05, **P<0.01 compared with
Vehicle, n=8 in each group. Dose–response curves of i.c.v. (C), i.t. (F) and i.pl. (I)
morphine in sham-operated and nerve-injured mice at 7 days following nerve
injury. The data are presented as AUC analgesic. **P<0.01 compared with
sham, n=8 in each group.
Additional file 2: Figure S2. 5-aza-dC improved morphine analgesia in
neuropathic pain mice. Time course of i.pl. (A and B), i.t. (D and E) and s.
c. (G and H) morphine in nerve-injured and 5-aza-dC (5 μg daily for 3
consecutive days, starting 30 minutes before surgery) treatmented mice
on day 7 after surgery. Results are presented as TWL in seconds, comparison
of morphine analgesia by AUC. *P<0.05, **P<0.01 compared with Vehicle,
n=8 in each group. Dose–response curves of i.pl. (C), i.t.(F and s.c. (I)
morphine in nerve-injured and 5-aza-dC treatmented mice on day 7
following nerve injury. The data are presented as AUC analgesic. *P<0.05
compared with CCI-Vehicle, n=8 in each group.
Additional file 3: Figure S3. A Methylation statuses of MOR gene PP in
DRG. The percentages of methylation at CpG sites in the MOR promoter
from the region of base pairs −569 to +33. -388, −344 and −255 CpG
sites significantly increased in DRG after nerve injury and 5-aza-dC reduced
the hypermethylation status. **P<0.01 compared with Sham-Vehicle mice,
##P<0.01compared with CCI-Vehicle mice, n=4 in each group.
B, Methylation statuses of MOR gene DP in DRG. The percentages of
methylation at CpG sites in the MOR promoter from the region of base
pairs −1721 to −780. No CpG site has a significant change. n=4 mice
in each group.
Additional file 4: Figure S4. A and B, methylation changes within the
PP region of spinal MOR gene. No CpG site has a significant change. n=4
in each group. H, methylation changes within the DP region of spinal
MOR gene. No CpG site has a significant change. n=4 in each group.Competing interests
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